Form 483

Samson Pharmaceuticals, Inc Form 483, 2026-04-29

FDA issued a Form 483 to Samson Pharmaceuticals, Inc on 2026-04-29 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Samson Pharmaceuticals, Inc · Commerce, United States · Issued April 29, 2026

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

29 Apr 2026
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Taichun Qin, Walden H Lee, Luis P Torres

29 Apr 2026
21 CFR 211.160(a)

Lab controls established, including changes

Cited by Taichun Qin, Walden H Lee, Luis P Torres

29 Apr 2026
21 CFR 211.160(b)(4)

Calibration - at intervals, written program, remedial action

Cited by Taichun Qin, Walden H Lee, Luis P Torres

29 Apr 2026
21 CFR 211.166(a)

Lack of written stability program

Cited by Taichun Qin, Walden H Lee, Luis P Torres

29 Apr 2026
21 CFR 211.192

No written record of investigation

Cited by Taichun Qin, Walden H Lee, Luis P Torres

Inspected site

SPSamson Pharmaceuticals, IncCommerce, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)(4)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere